Description: Recombinant monoclonal antibody to Envelope protein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the EBV transformed human B cell clone ZKA78. This is a Fab fragment with a his-tag.
Species and Isotype: Human Fab fragment, His-Tagged, kappa
Clone Number: ZKA78
UniProt Accession Number of Target Protein:
Published Application(s): NTRL; enhance; FC; ELISA
Published Species Reactivity: Zika Virus; Dengue Virus
Immunogen: mAb ZKA78 was selected from EBV-immortalized memory B cells derived from ZIKV-infected, DENV-naïve human donors based on its ability to bind Zika virus (ZIKV) Envelope protein and to neutralize ZIKV infection.
Specificity: ZKA78 is specific for EDI/II domain of the ZIKV envelope (E) protein, and cross-reacts with the E protein from Dengue virus (DENV), which is highly homologous (also contains high sequence similarity with other flaviviruses such as yellow fever and west nile). ZKA78 showed significant binding (determined by ELISA) to the E proteins of ZIKV, DENV1-4 and the virus-like particles (VLPs) of DENV1-4. Flavivirus E proteins mediate fusion, with EDI being involved in conformational changes required for viral entry and EDII containing a fusion loop. ZIKV is a flavivirus that can be transmitted sexually, by the Aedes mosquito vector, or vertically to a developing fetus. Most cases of ZIKV infection are asymptomatic or manifest in mild symptoms, but in some cases ZIKV infection can result in Guillain-Barré Syndrome or congenital birth defects in developing fetuses.
Application Notes: ZKA78 is able to partially neutralize ZIKV infectivity (IC50 ~2863 ng/ml), and is capable of enhancing ZIKV/ infection of K526 cells via the antibody-dependent enhancement (ADE) effect. This antibody can also neutralize (IC50~ 266 ng/ml) and enhance (by ADE) DENV infection. Neutralization of ZIKV infection can be measured using a micro-neutralization FC-based assay, and binding/specificity to E protein can be studied by ELISA. DENV2-infected AG129 mice administered with ZKA78 results in death after 5 days.
Antibody First Published in:
Stettler et al. Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection. Science. 2016 Jul 14. pii: aaf8505.  PMID:27417494 Note on publication: Describes the isolation of a panel of antibodies derived from ZIKV-infected, DENV-naïve and ZIKV-infected, DENV-immune human donors. They were tested for their ability to bind to Zika E protein or NS1 as well as their cross-reactivity with the homologs in DENV. The capability to neutralize ZIKV infection was studied as well as the antibody-dependent enhancement effect on infection.

Product Form

Purification: Purified by Immobilized Metal Affinity Chromatography
Supplied in: PBS with preservative (0.02% Proclin 300)
Storage Recommendation: Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C
Concentration: See vial label.